Literature DB >> 25959502

Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up.

M Smeerdijk1, R Keet2, B van Raaij3, M Koeter1, D Linszen1, L de Haan1, G Schippers1.   

Abstract

BACKGROUND: There is a clear need for effective interventions to reduce cannabis use in patients with first-episode psychosis. This follow-up of a randomized trial examined whether an intervention for parents, based on motivational interviewing and interaction skills (Family Motivational Intervention, FMI), was more effective than routine family support (RFS) in reducing cannabis use in patients with recent-onset schizophrenia.
METHOD: In a single-blind trial with 75 patients in treatment for recent-onset schizophrenia, 97 parents were randomly assigned to either FMI or RFS. Assessments were conducted at baseline and at 3 and 15 months after the interventions had been ended. Analyses were performed on an intention-to-treat basis using mixed-effect regression models.
RESULTS: From baseline to the 15-month follow-up, there was a significantly greater reduction in FMI compared to RFS in patients' quantity (p = 0.01) and frequency (p < 0.01) of cannabis use. Patients' craving for cannabis use was also significantly lower in FMI at 15 months follow-up (p < 0.01). Both groups improved in parental distress and sense of burden; however, only FMI parents' appraisal of patients' symptoms showed further improvement at the 15-month follow-up (p < 0.05).
CONCLUSIONS: The results support the sustained effectiveness of FMI in reducing cannabis use in patients with recent-onset schizophrenia at 15 months follow-up. Findings were not consistent with regard to the long-term superiority of FMI over RFS in reducing parents' distress and sense of burden.

Entities:  

Keywords:  Cannabis use; family intervention; interaction skills; motivational interviewing; recent-onset schizophrenia

Mesh:

Year:  2015        PMID: 25959502     DOI: 10.1017/S0033291715000793

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  7 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Substance Use in Relation to Mental Illness: A Study of Mexican-Origin Latinos with Schizophrenia and Their Family Members.

Authors:  Mercedes Hernandez; Concepcion Barrio; Paula Helu-Brown; Caroline Lim; Lizbeth Gaona
Journal:  Health Soc Work       Date:  2022-07-13

Review 3.  Parenting interventions for people with schizophrenia or related serious mental illness.

Authors:  Jessica Radley; Claire Grant; Jane Barlow; Louise Johns
Journal:  Cochrane Database Syst Rev       Date:  2021-10-19

4.  Motivational Interviewing for Loved Ones in Early Psychosis: Development and Pilot Feasibility Trial of a Brief Psychoeducational Intervention for Caregivers.

Authors:  Emily R Kline; Heather Thibeau; Aliyah S Sanders; Kelly English; Beshaun J Davis; Alicia R Fenley; Matcheri S Keshavan
Journal:  Front Psychiatry       Date:  2021-04-01       Impact factor: 4.157

5.  It might be a wonderful opportunity when patients with a psychotic disorder use cannabis.

Authors:  Lieuwe de Haan
Journal:  Psychol Med       Date:  2022-01-25       Impact factor: 7.723

6.  Psychosocial interventions for people with both severe mental illness and substance misuse.

Authors:  Glenn E Hunt; Nandi Siegfried; Kirsten Morley; Carrie Brooke-Sumner; Michelle Cleary
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

7.  Evaluation of an interaction-skills training for reducing the burden of family caregivers of patients with severe mental illness: a pre-posttest design.

Authors:  Yasmin Gharavi; Barbara Stringer; Adriaan Hoogendoorn; Jan Boogaarts; Bas Van Raaij; Berno Van Meijel
Journal:  BMC Psychiatry       Date:  2018-03-27       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.